loading page

Mass transfer of anti-cancer drug delivery to brain tumours by a multiple emulsion-based implant
  • +2
  • Ewa Dluska,
  • Agnieszka Markowska-Radomska,
  • Agata Metera,
  • Leszek Rudniak,
  • Konrad Kosicki
Ewa Dluska
Politechnika Warszawska
Author Profile
Agnieszka Markowska-Radomska
Warsaw University of Technology
Author Profile
Agata Metera
Warsaw University of Technology
Author Profile
Leszek Rudniak
Warsaw University of Technology
Author Profile
Konrad Kosicki
University of Warsaw
Author Profile


The advanced use of a pH-responsive biomaterial-based injectable liquid implant for effective chemotherapeutic delivery in glioblastoma multiforme brain (GBM) tumour treatment is presented. As an implant, we proposed a water-in-oil-in-water multiple emulsion with encapsulated doxorubicin. The effectiveness of the proposed therapy was evaluated by comparing the cancer cell viability achieved in classical therapy (chemotherapeutic solution). The experimental study included doxorubicin release rates and consumption for two emulsions differing in drop sizes and structures in the presence of GBM-cells (LN229, U87 MG), and a cell viability. The results showed that the multiple emulsion implant was significantly more effective than classical therapy when considering the reduction in cancer cell viability: 85% for the emulsion-implant, and only 43% for the classical therapy. A diffusion-reaction model was adapted to predict doxorubicin release kinetics and elimination by glioblastoma cells. CFD simulations confirmed that the drug release kinetics depends on multiple emulsion structures and drop sizes.
16 Jun 2021Submitted to AIChE Journal
20 Jun 2021Submission Checks Completed
20 Jun 2021Assigned to Editor
26 Jun 2021Reviewer(s) Assigned
08 Aug 2021Editorial Decision: Revise Major
18 Aug 20211st Revision Received
25 Aug 2021Submission Checks Completed
25 Aug 2021Assigned to Editor
25 Aug 2021Reviewer(s) Assigned
21 Sep 2021Editorial Decision: Revise Minor
29 Sep 20212nd Revision Received
02 Oct 2021Submission Checks Completed
02 Oct 2021Assigned to Editor
12 Oct 2021Editorial Decision: Accept